These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 18650371)

  • 1. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.
    Kilpatrick ES; Rigby AS; Atkin SL
    Diabetes Care; 2008 Nov; 31(11):2198-202. PubMed ID: 18650371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.
    Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.
    Lachin JM; Bebu I; Bergenstal RM; Pop-Busui R; Service FJ; Zinman B; Nathan DM;
    Diabetes Care; 2017 Jun; 40(6):777-783. PubMed ID: 28404658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes.
    Kilpatrick ES; Rigby AS; Atkin SL
    Diabetes Care; 2009 Oct; 32(10):1901-3. PubMed ID: 19549736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial.
    Lachin JM; Genuth S; Nathan DM; Rutledge BN
    Diabetes; 2007 Jul; 56(7):1913-21. PubMed ID: 17360979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycated hemoglobin variability and microvascular complications in patients with type 1 diabetes mellitus.
    Er E; Ata A; Evin F; Altınok YA; Demir G; Özen S; Darcan Ş; Gökşen D
    J Pediatr Endocrinol Metab; 2020 Dec; 33(12):1533-1537. PubMed ID: 33581707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between HbA1c Variability and Risk of Microvascular Complications in Adolescents With Type 1 Diabetes.
    Virk SA; Donaghue KC; Cho YH; Benitez-Aguirre P; Hing S; Pryke A; Chan A; Craig ME
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3257-63. PubMed ID: 27186858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
    Kilpatrick ES; Rigby AS; Atkin SL
    Diabetes Care; 2006 Jul; 29(7):1486-90. PubMed ID: 16801566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.
    Diabetes; 1997 Nov; 46(11):1829-39. PubMed ID: 9356033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort.
    Kim C; Cleary PA; Cowie CC; Braffett BH; Dunn RL; Larkin ME; Gatcomb PM; Wessells HB; Nathan DM; Sarma AV;
    Diabetes Care; 2014; 37(3):701-8. PubMed ID: 24170751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.
    Diabetes; 1995 Aug; 44(8):968-83. PubMed ID: 7622004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HbA1c variability as an independent predictor of diabetes retinopathy in patients with type 2 diabetes.
    Hu J; Hsu H; Yuan X; Lou K; Hsue C; Miller JD; Lu J; Lee Y; Lou Q
    J Endocrinol Invest; 2021 Jun; 44(6):1229-1236. PubMed ID: 32897535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
    ; Lachin JM; Genuth S; Cleary P; Davis MD; Nathan DM
    N Engl J Med; 2000 Feb; 342(6):381-9. PubMed ID: 10666428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.
    Hainsworth DP; Gao X; Bebu I; Das A; Olmos de Koo L; Barkmeier AJ; Tamborlane W; Lachin JM; Aiello LP;
    Ophthalmology; 2021 Apr; 128(4):554-560. PubMed ID: 32941962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.
    White NH; Sun W; Cleary PA; Danis RP; Davis MD; Hainsworth DP; Hubbard LD; Lachin JM; Nathan DM
    Arch Ophthalmol; 2008 Dec; 126(12):1707-15. PubMed ID: 19064853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.
    Wadén J; Forsblom C; Thorn LM; Gordin D; Saraheimo M; Groop PH;
    Diabetes; 2009 Nov; 58(11):2649-55. PubMed ID: 19651819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study.
    Hainsworth DP; Bebu I; Aiello LP; Sivitz W; Gubitosi-Klug R; Malone J; White NH; Danis R; Wallia A; Gao X; Barkmeier AJ; Das A; Patel S; Gardner TW; Lachin JM;
    Diabetes Care; 2019 May; 42(5):875-882. PubMed ID: 30833368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes.
    Monnier VM; Sell DR; Strauch C; Sun W; Lachin JM; Cleary PA; Genuth S;
    J Diabetes Complications; 2013; 27(2):141-9. PubMed ID: 23153673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.
    Arch Ophthalmol; 1998 Jul; 116(7):874-86. PubMed ID: 9682700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).
    White NH; Cleary PA; Dahms W; Goldstein D; Malone J; Tamborlane WV;
    J Pediatr; 2001 Dec; 139(6):804-12. PubMed ID: 11743505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.